Crizotinib

ApprovedTerminated

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

ALK or ROS1-positive NSCLC

Conditions

ALK or ROS1-positive NSCLC

Trial Timeline

Jan 28, 2019 → Sep 28, 2023

NCT ID

NCT03672643

About Crizotinib

Crizotinib is a approved stage product being developed by Pfizer for ALK or ROS1-positive NSCLC. The current trial status is terminated. This product is registered under clinical trial identifier NCT03672643. Target conditions include ALK or ROS1-positive NSCLC.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03085186	Pre-clinical	Completed	—	—	Inflammatory Myofibroblastic Tumour
NCT02473497	Pre-clinical	Completed	—	—	Neoplasm
NCT02824094	Pre-clinical	Completed	—	—	Neoplasms
NCT05160922	Approved	Active	Dec 27, 2021	Mar 21, 2028	NSCLC
NCT04084717	Phase 2	Recruiting	Dec 3, 2019	Jun 1, 2025	Non-squamous Non-small-cell Lung Cancer
NCT03672643	Approved	Terminated	Jan 28, 2019	Sep 28, 2023	ALK or ROS1-positive NSCLC
NCT03088930	Phase 2	Completed	Dec 13, 2017	Jan 13, 2021	Lung Cancer, Nonsmall Cell
NCT03375242	Pre-clinical	Recruiting	Oct 25, 2017	Mar 26, 2027	Non-small Cell Lung Cancer
NCT02612194	Phase 2	Terminated	Sep 27, 2016	Nov 21, 2019	Urinary Bladder Neoplasms
NCT02679170	Pre-clinical	Completed	Jun 29, 2016	May 4, 2022	Non-Small Cell Lung Cancer
NCT02223819	Phase 2	Completed	Mar 1, 2015	Jul 3, 2019	Uveal Melanoma
NCT02270034	Phase 1	Completed	Aug 13, 2014	Oct 26, 2020	Glioblastoma Multiforme (Grade IV) of Cerebellum
NCT01500824	Phase 2	Withdrawn	May 1, 2014	May 1, 2016	Non-Small Cell Lung Cancer
NCT02183870	Phase 2	Completed	May 1, 2014	Feb 29, 2020	Lung Cancer
NCT01945021	Phase 2	Completed	Sep 30, 2013	Jan 22, 2020	Non Small Cell Lung Cancer
NCT02034981	Phase 2	Completed	Aug 1, 2013	Dec 6, 2023	Hematologic Cancers
NCT01121588	Phase 1	Terminated	Mar 22, 2011	Sep 7, 2023	Neoplasms Malignant
NCT01297595	Phase 1	Completed	Mar 1, 2011	Apr 1, 2011	Healthy
NCT01154218	Phase 1	Completed	Aug 1, 2010	Nov 1, 2010	Healthy
NCT01125904	Phase 1	Completed	Jun 1, 2010	Jun 1, 2010	Healthy

Competing Products

2 competing products in ALK or ROS1-positive NSCLC

See all competitors

Product	Company	Stage	Hype Score
Lorlatinib	Pfizer	Phase 2	39
PF-06463922 + Crizotinib	Pfizer	Phase 1/2	32